Previous 10 | Next 10 |
Cytosorbents press release (NASDAQ:CTSO): Q1 GAAP EPS of -$0.21 misses by $0.06. Revenue of $8.69M (-18.0% Y/Y) misses by $1.32M. For further details see: Cytosorbents GAAP EPS of -$0.21 misses by $0.06, revenue of $8.69M misses by $1.32M
CytoSorbents Reports First Quarter 2022 Results and Revises 2022 Outlook PR Newswire Q1 2022 total revenue was $8.7 million , including product sales of $7.9 million . Core non-COVID-19 product sales were an estimated $7.6 million , and on a constan...
CytoSorbents Awarded Preferred Supplier Agreement with Asklepios, One of the Largest Private Hospital Operators in Germany PR Newswire MONMOUTH JUNCTION, N.J. , May 2, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treat...
CytoSorbents (NASDAQ:CTSO) stock rose April 29 after the company said that the first patient was enrolled in a trial aimed at supporting FDA marketing approval of the DrugSorb-ATR Antithrombotic Removal System for intraoperative removal of apixaban and rivaroxaban during cardiothoracic surger...
First Patient Enrolled in U.S. STAR-D Pivotal Trial Evaluating the DrugSorb™-ATR Antithrombotic Removal System to Remove Apixaban and Rivaroxaban During Cardiothoracic Surgery PR Newswire MONMOUTH JUNCTION, N.J. , April 29, 2022 /PRNewswire/ -- ...
CytoSorbents Highlights the Strategy of "Enhanced Lung Rest" Using CytoSorb with ECMO to Help Treat Lung Failure at the 10th EuroELSO Congress PR Newswire MONMOUTH JUNCTION, N.J. , April 28, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: C...
CytoSorbents to Report First Quarter 2022 Operating and Financial Results PR Newswire MONMOUTH JUNCTION, N.J. , April 19, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the...
CytoSorbents To Expand Direct Sales of CytoSorb® to the United Kingdom, the Sixth Largest Medical Device Market in the World PR Newswire MONMOUTH JUNCTION, N.J. , April 14, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leade...
Shares of CytoSorbents Corporation (NASDAQ:CTSO) traded today at $15.00, eclipsing its 52-week high. So far today approximately 27.3 million shares have been exchanged, as compared to an average 30-day volume of 166,000 shares. There is potential upside of 1.3% for shares of CytoSorbents...
CytoSorbents Receives Approximately $740,000 from the New Jersey Business Tax Certificate Transfer Program PR Newswire MONMOUTH JUNCTION, N.J. , April 7, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of li...
News, Short Squeeze, Breakout and More Instantly...
CytoSorbents Corporation Company Name:
CTSO Stock Symbol:
NASDAQ Market:
CytoSorbents Corporation Website:
PRINCETON, N.J., Aug. 01, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of deadly conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces that it has regained comp...
PRINCETON, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of deadly conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, is proud to announce the launch of ...
PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces it will present...